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Abstract
Background: Photodynamic therapy with daylight (DL-PDT) is efficacious in treating actinic keratosis (AK), but the
efficacy of field-directed, repetitive DL-PDT for the treatment and prophylaxis of AK in photodamaged facial skin
has not yet been investigated.
Methods/design: In this multicenter, prospective, randomized, controlled, two-armed, observer-blinded trial,
patients with a minimum of 5 mild-to-moderate AK lesions on photodamaged facial skin are randomly allocated to
two treatment groups: DL-PDT with methyl aminolevulinate (MAL) and cryosurgery. In the DL-PDT group
(experimental group), 5 treatments of the entire face are conducted over the course of 18 months. After
preparation of the lesion and within 30 min after MAL application, patients expose themselves to daylight for 2 h.
In the control group, lesion-directed cryosurgery is conducted at the first visit and, in the case of uncleared or new
AK lesions, also at visits 2 to 5. The efficacy of the treatment is evaluated at visits 2 to 6 by documenting all existing
and new AK lesions in the face. Cosmetic results and improvement of photoaging parameters are evaluated by
means of a modified Dover scale.
Primary outcome parameter is the cumulative number of AK lesions observed between visits 2 and 6.
Secondary outcome parameters are complete clearance of AK, new AK lesions since the previous visit, cosmetic
results independently evaluated by both patient and physician, patient-reported pain (visual analogue scale), patient
and physician satisfaction scores with cosmetic results, and patient-reported quality of life (Dermatology Life Quality
Index). Safety parameters are also documented (adverse events and serious adverse events).
Discussion: This clinical trial will assess the efficacy of repetitive DL-PDT in preventing AK and investigate possible
rejuvenating effects of this treatment. (Trial registration: ClinicalTrials.gov Identifier: NCT02736760).
Trial registration: ClinicalTrials.gov Identifier: NCT02736760. Study Code Daylight_01. EudraCT 2014–005121-13.
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Background
Actinic keratosis (AK) is one of the most frequently diag-
nosed skin diseases in dermatological practice. Clinical
examination of the study participants of the Rotterdam
cohort study aged >45 years showed a prevalence of up to
49% in men and 28% in women [1, 2]. Therefore, treat-
ment of AK causes high costs for health insurances [3].
Consequent treatment of AK is necessary because of the
possibility of malignant transformation. AK lesions are
regarded as in situ squamous cell carcinomas [4] that pro-
gress to invasive squamous cell carcinomas in up to 20%
of patients [5–7]. In 2015, ‘multiple actinic keratoses’ de-
fined as more than 5 AK lesions per year or field canceri-
zation of >4 cm2 have been acknowledged as a new
occupational disease in Germany [8]. National and inter-
national guidelines recommend the treatment of AK upon
diagnosis to prevent further progression into squamous
cell carcinoma [9].
Besides several other treatment options, photodynamic
therapy (PDT) with red light for illumination is character-
ized by high efficacy and good esthetic results, largely in-
dependent of patient adherence. Daylight-PDT (DL-PDT)
is a new treatment approach that uses natural sunlight for
illumination. DL-PDT is associated with less discomfort
and pain compared to standard treatment protocols, and
its efficacy in treating AK seems to be equal to that of
conventional PDT with red light [10–12].
However, clinical trials investigating the efficacy of field-
directed, repetitive DL-PDT for the prophylaxis of AK are
lacking [11, 13, 14] as well as knowledge about the esthetic
and rejuvenating effects of repetitive DL-PDT.
Therefore, the present study investigates the prophy-
lactic effect of repetitive DL-PDT on the occurrence of
AK as compared to lesion-directed cryosurgery. In
addition, the rejuvenating effects of DL-PDT with regard
to the clinical signs of photoaged skin are evaluated.
Methods/design
Study design
This study was designed as a multicenter, prospective,
randomized, controlled, two-armed study that compares
two different treatments. MAL application followed by
illumination with daylight (DL-PDT) represents the ex-
perimental treatment, and cryosurgery as a standard
lesion-directed therapy of AK is investigated as a refer-
ence therapy. Patients are randomly allocated to one of
the two treatment methods.
The study was approved by the Institutional Review
Board and the Ethics Committee of the University of Re-
gensburg (Approval number: 15–112-0068) as well as by
the German Federal Institute for Drugs and Medical De-
vices (Approval number: 61–3910-4,040,415). The study
was registered at EU Clinical Trials Register (EudraCT
Number: 2014–005121-13) on November the 17th 2014
and at clinicaltrials.gov (ClinicalTrials.gov Identifier:
NCT02736760) in March 2016. The clinical trial was
not registered retrospectively. The SPIRIT guidelines
were followed in this study protocol.
Written informed consent will be obtained from each
patient before enrolment. This is an ongoing clinical trial.
Inclusion and exclusion criteria
The main inclusion criteria are clinical diagnosis of actinic
keratosis (AK), a minimum of 5 non-hyperkeratotic, non-
pigmented AK lesions in the face (Olsen grading I or II),
Glogau Photodamage Classification Type II (moderate) to
IV (severe), Fitzpatrick skin type I to IV, age ≥ 40 years, a
negative pregnancy test in women of child-bearing age,
and written informed consent (Fig. 1).
The main exclusion criteria are known intolerance or
allergy to MAL or to any other ingredient of Metvix®
160 mg/g cream or Actinica® lotion (both Galderma
Laboratorium GmbH, Düsseldorf, Germany), photo-
sensitivity, diagnosis of porphyria, hyperkeratotic or
pigmented AK in the face, malignant skin tumors in the
face or on the scalp, clinically relevant suppression of
the immune system, pregnancy or lactation, medical his-
tory of PDT in the face during 6 months preceding study
treatment, rejuvenating treatment of the face 3 months
preceding study treatment or planned esthetic treat-
ments in the face in the next 24 months, other topical
treatments of AK in the face during 4 weeks preceding
Fig. 1 Potential study patient. Face of a potential study participant
with Glogau Photodamage Classification Type III (advanced). Multiple
visible AK, sallow skin discoloration with teleangiectasias and wrinkles
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study treatment or systemic treatment with retinoids,
and suspected lack of compliance (e.g. dementia).
Study treatment
At every visit, the location of each AK lesion is
documented within a chart and additionally marked on
plastic sheets. The plastic sheets are marked with refer-
ence points of the face of each study participant, ensur-
ing that the lesions will be found again at the next visit.
Photo-documentation is carried out in a standardized
manner at each visit.
Photodamage variables to be evaluated are fine lines,
mottled pigmentation, skin color, tactile roughness, sal-
lowness, teleangiectasias, deep wrinkles, facial erythema,
sebaceous gland hyperplasia, and the global score for
photoaging. Each photodamage variable is recorded on a
5-point scale (0–4, higher points indicating higher dam-
age, modified after a scale from Dover et al. and Zane et
al.) (Table 1) [15, 16].
Patient and investigator satisfaction with the cosmetic
outcome is evaluated from visit 2 onwards according to
the following scale: very satisfied, moderately satisfied,
slightly satisfied and not satisfied.
Pain during treatment is assessed by means of a visual
11-point scale (VAS-scale, 0, none, to 10, insufferable
pain). The patients mark their level of pain on the VAS.
The investigator rates and documents erythema and
edema after illumination with daylight or cryotherapy by
means of a 5-point scale: 0 (no), 1 (mild), 2 (moderate),
3 (marked), and 4 (severe). From the second visit
onwards, patients are asked if they have experienced any
side effects or any adverse events. (Table 2)
MAL application followed by illumination with daylight
Each patient randomized to the PDT arm of this trial re-
ceives 5 treatments with daylight PDT. For each PDT
session, an organic sunscreen (Actinica® lotion, LSF 50+,
Galderma Laboratorium, Düsseldorf, Germany) without
any mineral filters is applied onto the entire face and
other parts of the body that will be exposed to daylight.
After an absorption time of at least 15 min, the surface of
the AK lesions is gently prepared with a curette or a
scalpel to remove scales and crusts and to roughen the le-
sions’ surface. Then, a thin layer of MAL cream (Metvix®,
Galderma Laboratorium, Düsseldorf, Germany) is uni-
formly applied onto the entire face including the hairless
forehead, but sparing the eyelids, lips, and ears. Covering
the entire face with a thin layer using a spatula approxi-
mately requires 1 tube (2 g) of MAL cream. No occlusive
dressing is conducted. Within 30 min after MAL applica-
tion, patients expose themselves to daylight for 2 h. After
daylight exposure, patients return to the clinic or practice
and are instructed in washing off the MAL cream with
clear water. This treatment regimen is provided at visit 1
and repeated after 3 months, 6 months, 12 months, and
18 months (visits 1 to 5). DL-PDT can only be carried out
from March until October, in non-rainy weather, and an
outdoor temperature of at least 10 °C.
Cryosurgery
In the control-group, one single freeze–thaw cryosurgery
is conducted at visit 1, using an open spraying procedure
with liquid nitrogen for each AK lesion. After formation
of an ice ball, freeze time starts that should be between
5 and 10 s per lesion. At visits 2 to 6, the efficacy of the
treatment is evaluated by the investigator. Cryosurgery
will also be conducted at visits 2 to 5 in the case of non-
cleared or newly developed AK lesions.
Outcome assessment
The primary outcome parameter is the cumulative num-
ber of AK lesions observed between visits 2 and 6.
Secondary outcome parameters are complete clearance
of AK on patient and lesion basis, new AK lesions since
the last visit, cosmetic results as evaluated on assessment
scales, patient-reported pain (visual analogue scale,
VAS), local reactions, patient satisfaction score with cos-
metic results, physician satisfaction score with cosmetic
results, and patient-reported quality of life (Dermatology
Life Quality Index, DLQI).
In addition, safety parameters are documented (ad-
verse events and serious adverse events, AE and SAE).
Complete clearance is documented if a lesion is no
longer visible and also imperceptible to the touch
[17]. Photodamage variables to be evaluated are fine
lines, mottled pigmentation, skin color, tactile rough-
ness, sallowness, teleangiectasias, deep wrinkles, facial
erythema, sebaceous gland hyperplasia, and global
score for photoaging. Each photodamage variable is
recorded on a 5-point scale (0–4, higher points indi-
cating higher damage, modified after Dover and Zane)
[15, 16].
Patient and physician satisfaction with esthetic out-
come is assessed at visit 2 to 6. Patients and physicians
can choose from very satisfied, satisfied, moderately sat-
isfied, and not satisfied.
Statistical considerations
Study hypothesis
The study objective can be formulated as a test of the
null hypothesis H0: μ1 = μ0 versus the alternative
hypothesis H1: μ1 ≠ μ0, where μ1 and μ0 represent the
mean cumulative number of AKs in the MAL/daylight-
PDT and cryosurgery group.
Sample size
Sample size calculation is based on the primary end-
point, that is the cumulative number of AK lesions.
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According to clinical experience, we expect a mean cu-
mulative number of 10 AK lesions in the daylight-PDT
group versus 14 lesions in the cryosurgery group with a
standard deviation of 5 in both groups. To detect a dif-
ference of 4 with a standard deviation of 5 with a power
of 1 − β = 80% at a two-sided alpha significance level of
0.05, the required sample size is 26 patients per group (a
total of 52 patients to be analyzed). With a lost-to-
follow-up rate of 10%, 29 patients per group (a total of
58 patients) are required.
Populations to be analyzed
The intention-to-treat (ITT) analysis set consists of all
patients entering the study (i.e. all patients who are ran-
domized and receive a patient identification number)
and receiving at least one treatment. According to the
ITT principle, all patients are analyzed as belonging to
their randomized treatment, regardless of whether treat-
ment is refused or discontinued, or whether other proto-
col deviations are known.
The per protocol (PP) analysis set consists of the ITT
analysis set with no major protocol violations. Major
and minor protocol deviations will be identified by med-
ically trained staff before database lock.
The safety population consists of all patients receiving
at least one treatment and who undergo at least one
post-baseline safety assessment. The statement that a pa-
tient had no adverse events also constitutes a safety
assessment.
Statistical analysis
The cumulative number of AK lesions (sum of all AK
lesions from visit 2 to visit 6) is defined as the primary
endpoint. A point estimate is presented as mean and
standard deviation accompanied by the corresponding
95% confidence interval. Furthermore, the primary end-
point is compared between the MAL/daylight-PDT and
the cryosurgery group by means of an analysis of covari-
ance (ANCOVA) with treatment (MAL/daylight-PDT
and cryosurgery) as fixed factor and initial AK at base-
line and center as covariates. The results are presented
in terms of least-squares means and associated 95% con-
fidence intervals. All efficacy analyses are carried out on
the intention-to-treat (ITT) population and will be two-
sided at the significance level of 0.05.
Table 2 Study flow chart
Time - 4 weeks
– 0 d+
d 0+ 3 months after
V1#
3 months after
V2#
6 months after
V3#
6 months after
V4#
6 months after
V5#
Visit Screening 1 2 3 4 5 6
Study treatment
Test-group: Fullface-Daylight-PDT
1.PDT 2.PDT 3.PDT 4.PDT 5.PDT
Study treatment
Control-group: cryosurgery
Cryo Cryo° Cryo° Cryo° Cryo°
Documentation of AK lesions in
the face
X X X X X X
Randomization X
Obtaining Informed Consent X
Check of Inclusion/ Exclusion Criteria X X X X X X X
Medical history X
Photodocumentation X X X X X X
Assessment of photoaging parameters X X X X X X
Documentation of newly occurred
malignant skin tumors in the face
X X X X X X
Documentation of AEs and SAEs X X X X X X
Pain score (VAS) during treatment X X X X X
Skin-related quality of Life (DLQI) X X
Patient satisfaction with cosmetic results X X X X X
Investigator satisfaction with cosmetic results X X X X X
Local skin reactions X X X X X
Pregnancy test X X X X X X
+: Screening and Visit 1 may take place on the same day
# +/− 4 weeks
Cryo: Cryosurgery
° cryosurgery in the case of uncleared or newly developed AK lesions
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All secondary endpoints are analyzed in a purely ex-
ploratory manner and are summarized by means of de-
scriptive statistics. Thus, p-values and corresponding
confidence intervals are only descriptive in nature. Safety
variables are analyzed descriptively. Adverse events are
presented in frequency tables. In addition, adverse
events are tabulated by severity and relationship to study
treatment.
Quality assurance
Study monitoring is conducted by experienced monitors.
Monitoring is based on an a priori developed monitoring
plan that includes inspecting the completeness of docu-
mentation and comparing the documentation with the
source data.
Source data verification (SDV) is carried out at regular
intervals. In all patients, the following data are compared
with the source data: Basic patient documentation (sex
and date of birth), inclusion and exclusion criteria,
localization of AK study lesions, dates of all study visits,
primary endpoint, adverse events, and the reason for
premature study termination, if applicable.
Data management and archiving
The patient identification list is controlled by the Inves-
tigator/Principal Investigator and will not be forwarded
to other parties. Data recorded by pCRF will be pseudo-
nymized. The responsible data manager monitors com-
pliance to data security and protection rules according
to Standard Operating Procedures (SOPs) and Working
Instructions (WI).
All data management activities are conducted within a
consistent, auditable, and integrated electronical envir-
onment (data security, data entry, and data validation).
The responsible data manager takes care that no
unauthorized access to the computer system takes place.
By conducting adequate data backup procedures, the
data manager makes sure that no data will be lost. Only
specified persons involved in the trial and sworn to se-
crecy get authorization to enter or access the data trail
of all transactions. Range, validity, and consistency
checks are implemented into the system for application
during data entry. After the first verification of the CRFs,
all data collected on the CRFs are entered into the study
database. Data entries as well as data modifications and
data corrections are routinely recorded via the audit
trail. In the case of necessary corrections or existing data
inconsistencies, data queries are consecutively generated
by the data manager. Queries are sent to the Principal
Investigator/Investigator. Afterwards, data in the data-
base are corrected according to the answered and re-
solved queries. After the database lock, data are
imported into standard statistical software systems and
forwarded to the biometrician in charge.
Archiving of the clinical database including the audit
trail is conducted by the responsible data manager in a
machine-independent format. The originals of all essen-
tial trial documents are filed in the TMF that will be
stored at the archive of the Center for Clinical Studies
Regensburg (ZKS) for at least 15 years after preparation
of the final report. The investigators files all site-specific
documents (e.g. correspondence with ethic committee),
the patient identification list, the signed informed con-
sent forms, copies of the pCRFs, and general trial docu-
ments (e.g. protocol, amendments) in the ISF, which will
be also archived for at least 15 years at the individual
trial sites.
Ethical and regulatory aspects
The clinical study will be conducted in accordance with
the German Drug Law (Arzneimittelgesetz, AMG), na-
tional and international GCP guidelines, and the Declar-
ation of Helsinki, each in the applicable version.
In agreement with the German Drug Law (AMG) and
‘its adjunct GCP regulation (GCP-V)’, the study protocol
was submitted to and approved by the Federal Institute
for Drugs and Medical Devices (Bundesinstitut für Arz-
neimittel und Medizinprodukte, BfArM). Furthermore,
the responsible regulatory authorities were notified
about the study before patient recruitment could
commence.
This clinical study protocol was submitted to and ap-
proved by the Independent Ethics Committee (IEC) of
the Medical Faculty of the University of Regensburg,
Germany.
Discussion
The efficacy of daylight-PDT for the treatment of AK
has been proven in several controlled studies [11, 13,
14]. A recently published phase III study conducted in
Australia showed that DL-PDT with MAL for mild AK
is as convenient, similarly effective, and nearly painless
as conventional PDT [12]. Complete remission of AK at
week 12 after daylight-PDT was 89% and 93% after con-
ventional PDT. Pain was significantly lower during
daylight-PDT (VAS score 0.8 vs. 5.7). The most recently
published phase III study conducted in Europe also
showed that DL-PDT is as effective as conventional
PDT with methyl aminolevulinate cream, but better tol-
erated and nearly painless, and has high patient-
satisfaction scores in patients with mild or moderate AK
on the face or scalp [11]. Thus, DL-PDT with MAL is an
effective, almost painless, and patient-friendly treatment
for patients with AK that provides excellent cosmetic
outcome. DL-PDT requires little equipment, reduces the
physician’s time in the practice, and provides high pa-
tient satisfaction and motivation for retreatment.
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Since field cancerization is considered a chronic skin
disease and new AK lesions tend to develop even after
effective therapy, preventive concepts are highly desir-
able. So far, no studies are available on daylight-PDT for
the prevention of AK. In immunocompromised patients,
conventional PDT has been shown to have the potential
of delaying or reducing the development of new AK le-
sions when used in larger body areas. Investigations in
the context of preventing non-melanoma skin cancer in
renal transplant patients have shown that MAL-PDT de-
lays the development of new lesions after one single
field-directed treatment [18]. Furthermore, the potential
of repeated long-term MAL-PDT (PDT every 6 months)
in renal transplant recipients is being investigated over a
period of 5 years. An interim analysis at the 3-year
follow-up has shown the significantly delayed onset of
AK as compared to untreated skin. The cumulative
number of AK lesions was n = 8 in PDT-treated skin
versus n = 43 in untreated skin [19]. In another study,
81 organ transplant recipients with AK lesions on differ-
ent body sites were treated with two cycles of MAL-
PDT as compared to cryosurgery [20]. Significantly less
new AK lesions were present 3 months after PDT. After
27 months, the difference was not significant any more,
suggesting that repeated treatments may be necessary
for a prolonged preventive effect. ALA-PDT with blue
light conducted every 4 to 8 weeks for 24 months re-
duced the development of new lesions after the study
period by 95%. Only one study investigated the prevent-
ive potential of field-directed PDT in immunocompetent
patients with cancerization on the face and scalp. In that
study, ALA-PDT showed a significant delay of about
6 months until the development of new AK lesions as
compared to the control sites [21].
Chronically sun-damaged skin is also characterized by
sallowness, teleangiectasias, hyperpigmentations, rough-
ness, and wrinkles. Therefore, simultaneous treatment of
AK and photodamage is highly desirable. Several studies
have reported on the rejuvenating effects of PDT [22–24],
such as reduced fine wrinkles, mottled hyperpigmentation,
tactile roughness, skin texture, teleangiectasias, facial ery-
thema, and sallowness [25]. Only coarse wrinkles and seba-
ceous gland hyperplasia were not significantly improved.
The cosmetic effects of topical PDT are supported by im-
munohistochemical analysis that showed both upregulation
of collagen production and increased epidermal prolifera-
tion [26, 27]. Several studies have also shown a reduction in
elastotic material in the dermis [28, 29]. These molecular
effects together with the disappearance of Tp53, a marker
for epidermal carcinogenesis, may explain why PDT is able
to reverse the signs of photoaging [30].
Based on the findings after conventional PDT, the in-
novative research issue addressed in the present study is
to investigate the prophylactic effect of repetitive PDT
on the development of AK. As a secondary study end-
point, the rejuvenating effects of repetitive DL-PDT will
be examined for the first time.
The reference therapy used in this clinical trial is cryo-
surgery − a frequently used treatment modality for AK
that is recommended as a standard therapy in national
and international guidelines and was used in most stud-
ies as standard therapy comparator for PDT. Complete
remission rates are between 67 and 97% [31, 32]. Our
aim is to compare a lesion directed standard therapy
(cryotherapy) with a field directed therapy (DL-PDT)
with respect to an expected prophylactic effect of a re-
petitive field directed PDT.
The results of this clinical trial may be of practical
relevance for dermatologists and the numerous patients
with chronically sun-damaged skin and AK, who have a
high risk of developing new AK lesions that may pro-
gress into invasive squamous cell carcinoma. The demo-
graphic development will further increase the number of
patients affected. So far, only a few treatment options for
preventing AK are available, for instance sun avoidance
and the consequent application of sunscreen, DNA re-
pair enzymes, and oral nicotinamide [33, 34]. If the re-
sults of this study prove the efficacy of this treatment
option, the preventive use of repetitive DL-PDT may be
of great value for many patients because of the lack of
other prophylactic treatment strategies.
Other clinically relevant questions may arise, such as
DL-PDT as the possibly optimal treatment for immuno-
compromised patients or the role of DL-PDT as a pre-
ventive therapy for reducing the incidence of squamous
cell carcinoma. These questions cannot be answered by
the present trial and would require more specific
protocols.
This clinical trial will assess the effectiveness of repeti-
tive DL-PDT in treating and preventing AK in immuno-
competent patients with sun-damaged facial skin.
Patients of the control group will receive cryotherapy.
This trial will also investigate the potential rejuvenating
effects of repetitive DL-PDT.
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